Last reviewed · How we verify
Stamaril™
Stamaril is a live attenuated yellow fever vaccine that stimulates the immune system to produce antibodies and cellular immunity against yellow fever virus.
Stamaril is a live attenuated yellow fever vaccine that stimulates the immune system to produce antibodies and cellular immunity against yellow fever virus. Used for Yellow fever prevention in endemic regions and travelers to yellow fever-endemic areas.
At a glance
| Generic name | Stamaril™ |
|---|---|
| Also known as | Yellow Fever Vaccine, Yellow Fever (YF) Vaccine, YF17D vaccine |
| Sponsor | GlaxoSmithKline |
| Drug class | Live attenuated vaccine |
| Target | Yellow fever virus (17D strain) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains a weakened strain of yellow fever virus (17D strain) that replicates in the body without causing disease, triggering both humoral (antibody) and cell-mediated immune responses. This provides long-term protection against infection with wild-type yellow fever virus. The vaccine has been in use for decades and is considered one of the most effective vaccines available.
Approved indications
- Yellow fever prevention in endemic regions and travelers to yellow fever-endemic areas
Common side effects
- Headache
- Myalgia
- Fever
- Injection site reaction
- Fatigue
Key clinical trials
- Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants (PHASE2)
- Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen (PHASE2)
- Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Stamaril™ CI brief — competitive landscape report
- Stamaril™ updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI